The Charite Team (Prof. Dr. Stefan Schaller firstname.lastname@example.org; Dr. Alessandro Panelli Alessandro.Panelli@Charite.de) published “First non-invasive magnetic phrenic nerve and diaphragm stimulation in anaesthetized patients: a proof-of-concept study” (STIMIT I) being selected by ESICM in the category “Paper of the Year in Translational Biology”. Also, Charite published STIMIT II ICU trial on ESICM (Abstract) on the ESICM congress.
Interview with Paper-Author Prof. Schaller: Online Interview (just click on this link to view video online)
(full publication in progress)
Mechanical ventilation in intensive care causes degeneration of the breathing muscle. STIMIT AG and ETH Zürich pursue a pioneering approach with non-invasive stimulators. Ronja Müller-Bruhn and Prof. Christina Spengler give insight into their collaboration.
Hosted by the American Thoracic Society, the 2024 Respiratory Innovation Summit will unite the innovators, investors, clinicians and advocacy groups who are leading the charge to create powerful new treatments for deadly and crippling diseases of the lungs and airways. This meeting historically attracts 350+ global leaders representing all facets of the respiratory industry, including representatives from start-ups, business development, venture capital, government, academia and clinical medicine.
STIMIT is the winners of the Swiss Excellence Product Award 2022 in the category start-up. This is the 10th time that the jury of the Swiss Excellence Foundation has honored innovative Swiss products.
This year, 30 companies applied with their products for the Swiss Excellence Product Award. The jury visited the shortlisted candidates over the past few months and selected three finalists in each category. The jury evaluated the innovation content, the value creation potential as well as the quality of the business model and the marketing concept.
STIMIT AG was able to prevail in the Startup category with the STIMIT Activator. The innovative product stimulates the diaphragm muscles of intensive care patients - non-invasively - and thus gets patients breathing who would otherwise not breathe. "The product has great potential. It is already being used successfully, and Stimit has chosen a clever strategy for financing it," explains Stefan Philippi, lecturer at the Institute for Corporate Management at the FHNW and jury member of the Swiss Excellence Foundation in his laudation.
Drägerwerk AG & Co. KGaA has acquired the majority share of STIMIT AG. With this acquisition, Dräger further expands its expertise in the field of lung-protective ventilation. STIMIT is specialized in lung activation and non-invasive stimulation of respiratory muscles in intensive care patients
Covid-19 Economic Support, Bern.
Innosuisse II Commitment: In collaboration with project partner Bern University of Applied Sciences (BFH) and Swiss Innovation Park Biel
Venture Kick Stages I, II, and III
- Feasibility Study 1, High Tech Centre Aargau
Innovation Check (Innosuisse)
- Feasibility Study 2, High Tech Centre
Innosuisse Project I in partnership with Bern University of Applied Sciences (BFH), ETH Zurich, University Hospital Bern, and Swiss Innovation Park Biel
Tel: +41 32 513 93 00